Marinesco-Sjögren syndrome (MSS) is an autosomal recessive, neurodegenerative, multisystem disorder characterized by severe phenotypes developing in infancy. Recently mutations in the endoplasmic reticulum (ER) associated co-chaperone Sil1/BAP were identified to be the major cause of MSS. Sil1 acts as a nucleotide exchange factor for BiP, the ER Hsp70 orthologue, which plays an essential role in the folding and assembly of nascent polypeptide chains in the ER. Nucleotide exchange facilitates the release of BiP from substrates enabling the subsequent folding and transport of the protein.
Although most mutations leading to MSS result in deletion of the majority of the protein, three separate mutations have been identified that disrupt only the last five or six amino acids of the protein, which were assumed to encode a divergent ER retention motif. This study presents an in depth analysis of two of these mutants and reveals that the phenotype in the affected individuals is not likely due to depletion of Sil1 from the ER via secretion. Instead, our analyses show that the mutant proteins are particularly unstable and either form large aggregates in the ER or are rapidly degraded via the proteasome. In agreement with our findings, homology modeling suggests that the very C-terminal residues of Sil1 play a role in its structural integrity rather than its localization. These new insights might be a first step towards a possible pharmacological treatment of certain types of MSS by specifically stabilizing the mutant Sil1 protein.
The endoplasmic reticulum (ER) is a major site of protein biosynthesis within the cell. Proteins destined to be expressed in any of the single membrane bound organelles, at the cell surface, or secreted are imported into the ER cotranslationally as extended polypeptide chains in most eukaryotic cells. Nascent proteins are modified by N-linked glycans, folded into their mature secondary and tertiary structures, and form intra-and inter-molecular disulfide bonds. These processes are closely monitored by the ER quality control machinery, and once proteins mature properly they exit the ER for residence further along the secretory pathway (1;2).
As a consequence, the ER contains large quantities of unfolded proteins and unassembled subunits. To maintain ER homeostasis and prevent the aggregation of non-native structures, this organelle contains a particularly high concentration of molecular chaperones and their co-factors. If the nascent protein is ultimately unable to achieve its proper final structure, it can be retrotranslocated to the cytosol for degradation by the 26S proteasome, as long as the misfolded protein is maintained in a soluble state (3) .
The ER possesses members of two major chaperone families; the lectins calnexin and calreticulin (4) (5) (6) and the Hsp70 orthologue BiP (7;8) . BiP has been identified as a key regulator of ER function where it plays a role not only in protein folding and assembly (9;10) but also maintains the permeability barrier of the ER during translocation (11) , targets misfolded proteins for proteasomal degradation (12) , regulates the ER localized transducers of the unfolded protein response (UPR) (13;14) , and contributes to calcium stores within the ER (15) . Like all Hsp70 family members, BiP has an Nterminal nucleotide binding domain (NBD) and a C-terminal substrate binding domain (SBD). When ATP occupies the NBD, the SBD opens so that it can engage nascent proteins (16) . Hydrolysis of ATP to ADP results in the lid of the SBD closing, which protects the unfolded protein from aggregation. The lid is reopened when ATP replaces ADP, thereby allowing the substrate to be released and fold. The ATPase cycle of BiP is tightly regulated by a number of co-factors, including DnaJ-like proteins that stimulate ATP hydrolysis (17;18) and nucleotide exchange factors that release ADP and allow ATP to rebind. Two nucleotide exchange factors have been identified in the mammalian ER to date: Sil1/BAP (19) and GRP170/ORP150 (20) .
A large and ever growing number of protein folding diseases are known to occur due to mutations in a single client protein (21) . These mutations can lead to loss of function, the production of unstable proteins that are either aggregation-prone or rapidly degraded, or proteins that fail to pass ER quality control and therefore never make it to their necessary destination. It seemed unlikely that components of the ER chaperone machinery could be targeted by mutation, as it was thought that they were too essential for cell viability. For instance BiP knock-out mice die at embryonic day 3.5 (22) and the AB5 subtilase cytotoxin exerts its lethal effects by cleaving BiP between the NBD and the SBD (23), thus presumably deregulating the binding and release of BiP to client proteins. Therefore, it came as no small surprise when linkage disequilibrium studies mapped MSS disease causing mutations to the Sil1 gene (24;25) .
Although affected individuals show multi-system defects, not all tissues are affected equally and even mutations that totally disrupt the Sil1 gene are not incompatible with life in either humans or mouse models (26) . To date, 17 independent mutations have been identified in the Sil1 gene (24;25;27-29) . Many of these would be expected to result in deletion of the majority of the protein or at least those portions of the protein that are predicted to interact with BiP. In addition, three independent disease causing mutations were identified in the Sil1 gene that disrupt only the last five or six amino acids, LLKELR (25;28) .
A large number of soluble resident ER proteins are retained in the ER by virtue of their last four amino acids, usually KDEL (30) . If proteins possessing these amino acids at their Cterminus escape from the ER, they engage a KDEL receptor in the intermediate compartment or cis-Golgi and are rapidly returned to the ER. A number of variations in this sequence are found on some resident ER proteins (31) , arguing that the receptor is more promiscuous in its recognition than originally thought (30) . This point was further demonstrated by a study in which 77 variants of the KDEL sequence were produced by altering a single amino acid at a time and examined for their ability to retain a reporter protein (31) . It was found that 35 of these variants readily led to ER localization of the reporter. Targeted deletion of the "KDEL" retention sequence from resident ER chaperones can lead to their inappropriate secretion and as a result their depletion from this organelle (30) . Thus, it was hypothesized that the KELR sequence of Sil1 represented a particularly divergent ER retention sequence (19) , and furthermore that mutations that affected this sequence caused MSS due to the failure to retain Sil1 in the ER. To determine if indeed this was the case, we produced two of these mutations in the human Sil1 gene and characterized the mutant proteins. We found that deletion or mutation of the C-terminal Sil1 sequence does not lead to secretion of the protein, but instead that it is critical for maintaining Sil1's stability so that it can function as an exchange factor for BiP. In keeping with this, modeling of the Sil1 structure suggests that its C-terminal region is structured and forms a number of stabilizing contacts with the rest of the molecule.
EXPERIMENTAL PROCEDURES
Site Directed Mutagenesis of the human Sil1 cDNA-Site directed mutagenesis of a human Sil1 cDNA clone (19) was added 2h prior to the starvation period and included throughout the metabolic labeling and chase. For lysosomal inhibition, 10 mM NH 4 Cl was added during the 45 min starvation period and throughout the labeling and chase. To determine glycosylation patterns of wild-type and mutant Sil1, cells were pre-incubated with 2.5µg/ml tunicamycin (Sigma-Aldrich, MO, USA) for 30 minutes and labeled with [
35 S] methionine and cysteine for 2 hours.
Preparation of NP-40 soluble and insoluble fractions for immunoprecipitation-Following labeling, cells were washed twice with PBS, and each p60 dish was lysed in 1ml NP-40 lysis buffer (0.05M Tris-HCl pH7.5, 0.15M NaCl, 0.5% deoxycholic acid, and 0.5% NP-40) supplemented with 2% sodium azide, 0.25mM phenylmethylsulphonyl fluoride, complete EDTA free protease inhibitor tablets (Roche Diagnostics, Germany) and 10U/ml apyrase (Sigma-Aldrich, MO, USA). Cell lysates were collected into Eppendorf tubes and centrifuged for 15 minutes at 14,000 rpm at 4˚C. The supernatant (NP-40 soluble) and pellet (NP-40 insoluble) were separated and stored frozen at -80˚C until further use. NP-40 insoluble pellets were thawed and 50µl of SDS solubilization buffer (50mM TrisHCl, pH 8.0 with 2% SDS) was added. Pellets were heated to 95˚C for 20 minutes and regularly agitated to solubilize the NP-40-insoluble material. The 2% SDS solution was then diluted to 1 ml with NP-40 lysis buffer for immunoprecipitation. Both NP-40 soluble and insoluble fractions were immunoprecipitated with a polyclonal anti-Sil1 antiserum (19) and Protein A Sepharose beads and subjected to SDS-PAGE analysis. Signals were enhanced with Amplify (Amersham Biosciences, PA, USA) and visualized by autoradiography or quantitated by phosphorimaging and the bands present in the chase samples were expressed as a percent of the signal present in the pulse lane.
Immunofluorescence staining-COS-1 cells were cultured on cover slips in p35 dishes and transfected as indicated. Forty-eight hours after transfection, slides were washed twice with cold PBS and then blocked with 5% FBS in PBS for 5 minutes. Slides were washed once more with PBS, fixed in an acid:alcohol (95% pure ethanol: 5% glacial acetic acid) solution at -20˚C for 30 minutes, rehydrated in PBS, and stored at 4˚C. Cells were stained using a polyclonal rabbit anti-Sil1 antiserum and mouse anti-ER60 (a kind gift of Dr. A. Tsuru, Nara Institute of Science & Technology, Japan) as an ER marker. Cy3-conjugated goat anti-mouse IgG (Jackson ImmunoResearch, PA, USA) was used to detect ER60 and FITC-conjugated goat anti-rabbit IgG (Southern Biotech, AL, USA) to detect Sil1. Slides were mounted using VectaShield, (Vector Laboratories CA, USA) containing 10µg/ml DAPI and visualized by fluorescence microscopy (Olympus BX50). Photos were taken with a Sensys camera (Photometrics, Tuscan, AZ), and images were processed by V++ Digital Imaging software (Roper Scientific, Auckland, New Zealand) and Photoshop (Adobe, San Jose, CA).
Structural modeling and secondary structure prediction-A homology model of Sil1 was build with YASARA Structure (www.yasara.org) based on the available human HspBP1 core domain crystal structures (pdb codes 1XQR and 1XQS). A hybrid model of different individual models, which gave the overall best Z-score in YASARA, was used for further analysis. Structural alignments were generated with the MUSTANG algorithm implemented in YASARA Structure (33) . Prediction of α -helical propensity for the different peptides was performed with AGADIR (34) at pH 7.5, 0.15 M ionic strength, at 37˚C 310 K with an acetylated N-terminus and an amidated C-terminus. Data analysis was performed with IGOR Pro (www.wavemetrics.com).
RESULTS
Generation of a cDNA encoding the MSSassociated Δ1366 mutant. The vast majority of Sil1 mutations that cause Marinesco-Sjögren syndrome result in the deletion of large portions of the protein that would be expected to affect the predicted BiP interacting regions encoded by exons 6 and 9. However, three equally severe disease mutations have been identified that only affect or delete the last 6 amino acids of Sil1 in two cases (25) , (28) or introduce a proline immediately before the KELR sequence in the third (28) . One of the first type of mutant arises due to deletion of the thymidine at base pair 1366 (Δ1366) of the coding sequence. The resulting frame shift causes a codon change from leucine to cysteine, which is immediately followed by a stop codon, thereby affecting only the last 6 amino acids of the Sil1 protein ( Figure 1 ). The second mutation is a base change from thymidine to adenosine at base pair 1367 (1367 T→A ), which alters the leucine codon to a stop codon (Figure 1 ). Thus the two mutations differ only by the presence of a C-terminal cysteine on the Δ1366 mutant, and both lack the KELR sequence, which was presumed to encode the ER retention motif. The third disease-associated change in this region is the mutation of thymidine 1370 to cytidine (1370 T→C ). This does not alter the C-terminal KELR sequence but replaces the leucine residue immediately preceding it with a proline (Figure 1 ). The Δ1366 mutant and the 1370 T→C mutants were used for this study as they represent two different classes of C-terminal Sil1 mutations: complete deletion (Δ1366) or point mutation (1370 T→C ) of the putative ER retention sequence or its immediate environment.
Sil1 Δ1366 is not secreted from cells but instead is aggregation prone. The deletion or mutation of the last 6 amino acids would not be expected to directly affect the interaction of Sil1 with BiP based on the crystal structure of the HspBP1:Hsc70 complex (35) or the recently published yeast Sil1:BiP complex (36) . Instead, it was assumed that these mutations affected the retention of Sil1 leading to its depletion from the ER. To determine if indeed this was the case, pulse-chase experiments were conducted on both wild-type and mutant Sil1 Δ1366. Somewhat unexpectedly over-expression of wild-type Sil1 resulted in the secretion of a significant portion of the labeled pool of this protein (Figure 2A ). This is not unprecedented as over-expression of resident ER proteins can result in their secretion demonstrating that ER retention and KDEL receptor interactions can be saturated (37) . When we examined the Δ1366 mutant in the same way, we observed a similar loss of signal over the time course of our chase (Figure 2A ). However, there was no evidence that the mutant Sil1 was being secreted.
Instead, it was possible that the disappearance of mutant Sil1 was due to the mutation destabilizing the protein leading to either aggregation or degradation. To determine whether the Δ1366 mutant might be forming NP-40 insoluble aggregates, we solublized proteins in the lysate pellet with SDS, diluted the sample, and immunoprecipitated with anti-Sil1 antiserum.
While the over-expressed wild-type protein showed almost no evidence of aggregate formation, significant quantities of mutant Sil1 were found in the NP-40 insoluble fraction ( Figure 2B ), demonstrating that the last 6 amino acids were important for maintaining the solubility of Sil1.
The Δ1366 mutant Sil1 is excluded from the perinuclear/Golgi region and forms large aggregates in the ER. As no evidence of secretion could be observed for the Δ1366 mutant, the subcellular localization of both wild-type and mutant was determined. Antibodies to the resident chaperone ER60/ERp57 were used to identify the ER. Although wild-type Sil1 co-localized with ER60 and showed the same characteristic reticular staining pattern, there was a pool of Sil1 that could be readily detected in the perinuclear region that did not contain ER60 ( Figure 3A ). This pool likely represents Golgi-localized Sil1 that is being processed for secretion.
Thus although ER retention systems can be exceeded, there was no evidence that localization of ER60 was also affected. When the Δ1366 mutant was similarly examined, we found that the signal nearly completely over-lapped with that of ER60 and was excluded from the perinuclear region ( Figure 3B) . However, the retained mutant Sil1 did not exhibit the normal reticular pattern associated with ER staining and in fact appeared to affect ER60 staining as well.
The pattern most closely resembled that of large aggregate formation in keeping with the data in Figure 2B .
Over-expression of BiP prevents secretion of wild-type Sil1. Because Sil1 is a co-factor for BiP, we next determined if its interaction with BiP might normally prevent it from being secreted. To examine this possibility, we co-transfected cells with Sil1 and an increasing amount of a vector encoding hamster BiP. Increasing BiP levels dramatically reduced the secretion of wild-type Sil1 from the cells (Figure 4 ), arguing that its interaction with BiP may provide the mechanism for its retention in the ER and that saturation of KDEL receptor interactions is unlikely to be the reason for Sil1 secretion. When the Δ1366 mutant was examined in the same way, there was still no evidence of mutant Sil1 secretion. However, it was noted that even though the signal for the wildtype Sil1 protein was more stable now that it was retained in the cells, the signal for the mutant protein disappeared at a similar rate with BiP overexpression (Figure 4) .
Over-expression of BiP reduces aggregation of the Δ1366 mutant but increases its degradation.
The failure to observe secretion of the Δ1366 mutant in the above experiment could be due to the fact that it was still aggregating even in the presence of BiP over-expression. If this was the case, we would not be able to draw any conclusions about a requirement for the KELR sequence in Sil1 retention. Thus we examined the solubility of the mutant Sil1 when it was coexpressed with BiP and found that BiP overexpression dramatically inhibited its aggregation in an NP-40 solubility assay (data not shown). This point was further underscored by examining the localization pattern of the Δ1366 mutant in cells also over-expressing BiP. We found that BiP restored a more reticular staining pattern to the mutant protein, and that it was still excluded from the perinuclear region ( Figure 5 ). There was no longer evidence of the large aggregate pattern seen without BiP over-expression. As the pulse-chase experiment in Figure 4 suggested that the signal for the Δ1366 mutant was disappearing even faster in the presence of BiP and that this was not because of enhanced aggregation ( Figure 5) , we examined the possibility that the solublized Δ1366 mutant was being recognized as an unfolded protein and targeted for degradation. To test this possibility, cells co-expressing the Sil1 mutant with BiP were subjected to pulse-chase experiments alone, in the presence of MG132, a proteasome inhibitor, or with NH 4 Cl, a lysosomal inhibitor.
Indeed, the mutant protein was dramatically stabilized in the presence of MG132 ( Figure 6A ), arguing that the mutation affects the folding of the Δ1366 mutant, which leads to its degradation by the proteasome. Although in this experiment, the signal for the mutant protein was lower when cells were pre-incubated with MG132 to inhibit the proteasome, this decrease in expression was not consistent and was also observed in some instances with the wild-type protein.
Structural modeling of the human Sil1 protein suggests a stabilizing role for its C-terminal residues. Our data implied that the KELR sequence of Sil1 does not represent an unusually degenerate ER retention motif but might instead play a role in the structural integrity of the protein.
To address this hypothesis, we generated a structural homology model for Sil1 based on the published crystal structure of human HspBP1 (35) , which is a cytosolic orthologue of Sil1 (38) . Importantly, this structure corresponds to the Cterminal portion of Sil1 and allowed us to generate a model that included the KELR sequence ( Figure  7) . Although a structure for the yeast Sil1 protein complexed with BiP was recently published, we were unable to verify our model on a perhaps more relevant protein, as this structure does not include the C-terminus of yeast Sil1 (36) .
It is evident from Figure 7 that the KELR sequence of Sil1 is not predicted to be unstructured. Instead it appears to make up the Cterminal portion of an α -helix that is predicted to comprise the last 19 residues of the protein ( Figure  7 ). An analysis of the helical propensity for these 19 residues with AGADIR (34) predicts an overall low helical propensity ( Figure 7B ). Of note, the Sil1 deletion mutants, Δ1366 or 1367 T→A , and the Leu to Pro point mutant (1370 T→C ) are significantly less likely to form a helix by this analysis ( Figure 7B ). The overall low helical propensity of the last 19 residues of Sil1 suggests that this helix might depend on tertiary interactions in order to be formed or stabilized. Indeed, in the two deletion mutants (Δ1366 and 1367 T→A ) three leucine residues are missing, which based on the structural model of Sil1 are involved in tertiary interactions with an adjacent helix thereby stabilizing the last helix ( Figure 7C,  D) . Furthermore, in the two deletion mutants the very last residue, Arg461, is missing which would, due to its positive charge, normally stabilize the helix dipole of the final helix in the wild-type Sil1 protein. Additionally, the sidechain of Arg461 is predicted to directly form stabilizing interactions with the oppositely charged sidechain of Glu428 and with the backbone carbonyl oxygen of Ala423. The first of these three leucines is mutated to proline in the 1370 T→C mutant. In addition to the well-characterized helix breaking properties of prolines, based on our modeling this substitution would likely affect the interactions between the Cterminal helix and the rest of the molecule in this mutant. In toto, the structural model of human Sil1 predicts that the C-terminal residues affected in three different MSS mutations contribute to the stability of the C-terminal helix.
To test our hypothesis and the validity of our structural model we generated the 1370 T→C mutant of Sil1. This mutant is particularly well suited in this regard as it is predicted to interfere with the formation of a C-terminal helix but not with the putative ER retention sequence directly (Figure 1) . In pulse-chase experiments, we found that the 1370 T→C mutant behaved similar to the Δ1366 mutant in that it was not secreted and turned over rapidly ( Figure 7E ). However, in contrast to the Δ1366 mutant, there was little or no formation of SDS-soluble, NP40-insoluble aggregates ( Figure  7E) . Thus, the 1370 T→C mutant is not secreted but does not form aggregates like the Δ1366 mutant arguing against the mutation disrupting an ER retention motif and suggesting degradation of this mutant in a soluble form. Indeed, treatment with MG132 inhibited turnover of the 1370 T→C mutant, whereas ammonium chloride did not ( Figure 7F ). This suggests that the 1370 T→C mutant is recognized as being a misfolded protein and degraded by the proteasome, which is in very good agreement with our hypothesis that the C-terminal Sil1 residues are important for the structural integrity of the protein rather than for its ER retention.
The C-terminal cysteine generates an unusual N-linked glycosylation sequence and induces dimerization of the Δ1366 mutant. In a number of our experiments, we noticed that the Δ1366 mutant ran somewhat slower on SDS polyacrylamide gels than the wild-type protein.
The loss of 5 amino acids was unlikely to significantly affect the migration of the protein but changes in charge can affect the binding of SDS leading to aberrant migration. When we inspected the sequence more closely we noted that the Cterminal sequence was now N-S-C, which has recently been shown to encode an N-linked glycosylation site in a few proteins (39;40) . To assess whether in fact this was the case, we treated cells expressing wild-type and the Δ1366 mutant with tunicamycin and performed metabolic labeling experiments.
In the absence of tunicamycin, the migration of the Δ1366 mutant was slightly slower than that of the wild-type protein ( Figure 8A ).
Tunicamycin treatment resulted in the wild-type protein migrating faster in keeping with the presence of two conventional N-linked glycosylation sites on Sil1. When the Δ1366 mutant was similarly examined, we found that the non-glycosylated protein now migrated the same as wild-type Sil1 (Figure 8A ), demonstrating that the altered mobility was due to the glycosylation of this unusual sequence and not to changes in SDS binding. The presence of this terminal cysteine was also likely to provide an unpaired cysteine that could now cause the mutant protein to be retained in the ER by thiol-mediated retention mechanisms (41) . To determine whether indeed this cysteine remained unpaired, we analyzed the wild-type and mutant protein under non-reducing conditions. As expected, the wild-type protein existed in cells predominantly as a monomer in the presence of BiP over-expression ( Figure 8B ). When the Δ1366 mutant was examined under the same conditions, we found that a significant portion of the mutant existed in the form of disulfide linked dimers, while the remainder migrated as a monomer ( Figure 8B) . Thus, the inability of the Δ1366 mutant to be secreted even after solubilization is unlikely to be due to either thiolmediated retention mechanisms or to disulfidelinked dimers leading to aggregation. Instead it is likely that this mutant is retained in the ER via its association with BiP, but perhaps as an unfolded protein instead of a normal co-factor.
DISCUSSION
In 1987, Munro and Pelham noted that a number of soluble, resident ER proteins possess the tetrapeptide, KDEL, at their C-terminus and postulated that this sequence might be responsible for preventing their secretion (30) . Indeed, by engineering this sequence at the C-terminus of ovalbumin, they were able to prevent its secretion. Correspondingly, removing the sequence from BiP allowed it to be secreted, although the effects of a KDEL-less mutant on secretion were much less robust than the ability of this sequence to prevent the transport of ovalbumin (30) . A number of somewhat divergent examples of this tetrapeptide have been identified on resident ER proteins since its identification, arguing that the KDEL receptor can be promiscuous to a certain extent in identifying C-terminal tetra-peptides as retention motifs. One study produced 77 variants of this sequence by changing one amino acid at a time and examined their ability to retain a reporter protein in the ER (31) . They found that the -4 (lysine) and -3 (aspartic acid) residues could be quite variable and that the -1 (leucine) could be substituted with either methionine or phenylalanine and work nearly as well. However, the -2 (glutamic acid) residue was critical in the context of a KDEL sequence, and even the substitution of this residue with an aspartic acid dramatically reduced the ability of the sequence to retain the reporter. However, it is important to note that the KELR sequence has never been directly tested as a retention sequence, and inspection of Sil1 sequences from primates and rodents reveals that it is completely conserved. However it is quite different in more distal species, some of which actually possess a bona fide KDEL-type ER retention sequence (28) , arguing for divergent evolution. A recent study used immunofluorescence staining to examine the localization of the wild-type Sil1 protein and two of MSS mutants; 1367 T→A and 1370 T→C , all of which were tagged at their extreme C-terminus with an HA epitope (28) . The mutant proteins showed a propensity to aggregate and colocalize with ER markers, whereas the wild-type protein could be detected in the Golgi as well as the ER, leading them to conclude that KELR may represent a retention sequence that was weakened during evolution (28) . Our studies using untagged forms of Sil1 confirmed that the KELR sequence is not responsible for retaining it in the ER and provide a more detailed structural explanation for the behavior of all three C-terminal Sil1 mutants that have been identified in individuals with MSS as described below. In addition our study provides insights into the usual mechanism of retaining wild-type Sil1 in the ER. Although endogenous Sil1 is retained in the ER (19) , in the present study we observed secretion of transfected Sil1 when it was expressed from a strong promoter. Our finding that over-expression of BiP suppressed the secretion of wild-type Sil1 argues that this is likely to be the normal mechanism of Sil1 retention. It is very possible that this mechanism extends to other soluble ER resident proteins that do not have ER retention sequences, including many of the other ERlocalized DnaJ-like proteins (42) . In keeping with this, studies to measure the concentration of BiP and resident ER localized DnaJ-like proteins found that the concentration of BiP was significantly greater than the combined concentration of the ERdj proteins (43). As GRP94 possesses a KDEL tail and is one of the most abundant resident ER proteins, it is possible that this chaperone also contributes to the retention of other resident proteins that do not possess a KDEL sequence. Our data strongly suggest that the loss of the last five amino acid of Sil1 in the Δ1366 mutant affects its folding, leading to loss of function, based on the following criteria. First, the Δ1366 mutant readily aggregates when over-expressed, whereas the wild-type Sil1 protein does not. Second, over-expression of BiP is able to solublize the mutant protein, which is a characteristic of molecular chaperones binding to misfolded proteins. Finally, once solublized, the Δ1366 mutant protein is degraded faster than the wildtype protein, which is another characteristic of misfolded proteins. These conclusions are further supported by the structural model we derived for human Sil1. This model suggests that, at least in the case of rodent and primate Sil1, the last few Cterminal residues are not unstructured and exposed, as would be expected for a retention sequence, although it is very possible that it is the case in species like yeast and mosquitos that have a more conventional ER retention sequence. Instead, our model predicts that they are part of a longer α -helix and contribute to its stability through hydrophobic interactions, hydrogen bonds and salt bridges with other portions of the protein. Deletion of these last residues, or insertion of a proline as a helix breaker, would thus be expected to compromise the overall ability of the last α -helix to form. This would in turn lead to exposed hydrophobic residues within this now partially unstructured final α-helix, as well as in the region of Sil1 where this α -helix would normally dock. Indeed, we find the 1370 T→C mutant not to be secreted, unlike over-expressed wild-type Sil1, but instead to be degraded by the proteasome. This finding strengthens our hypothesis that the Cterminal Sil1 residues are structurally important and do not represent degenerate ER retention motif. This model also explains why overexpression of the other two C-terminal diseaseassociated mutations, which entirely lose their last five to six amino acids, increased their propensity to aggregate. Under normal physiological levels of synthesis, where BiP levels are in excess of the three C-terminal Sil1 mutants, it is likely that they simply turn over more rapidly, leading to their depletion from the ER and the resulting disease phenotype. A rather unanticipated finding in the characterization of the Δ1366 mutation is that the mutation of leucine 456 to cysteine now encodes a N-S-C sequence that has recently been shown to serve as an N-linked glycosylation motif on a few proteins (39;40) , instead of the usual N-X-S/T, which is the hallmark N-glycan acceptor sequence. While the addition of sugars usually increases the solubility of proteins, it does not appear to be sufficient to do so in this case. However, this modification is unlikely to contribute solely to the disease associated phenotypes as the 1367 T→A mutation will not be similarly modified and causes a similarly severe disease. In summary, three mutations have been identified that affect only the last few amino acids of Sil1, but which induce a disease as severe as those that affect much larger portions of the protein. This is not due to the disruption of an ER retention sequence as previously suggested, but instead to changes in the structure of the remaining protein that affect its stability and/or solubility. Thus, indeed these mutations lead to loss of Sil1 from the cell but not due to secretion. Instead our studies indicate that normally this exchange factor is retained in the ER via its association with BiP. Our molecular modeling suggests the importance of the last few amino acids of Sil1 in stabilizing the final α-helix, and likely the regions it interacts with, and explains why the three C-terminal mutants cause MSS. The fact that our studies indicate that these particular mutations affect the folding of Sil1 while leaving the protein sequence almost completely intact raises the interesting possibility that these mutant proteins, and thus the patients expressing them, could benefit from the type of pharmacological stabilization being pursued for other protein folding disorders (44) .
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